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ABSTRACT
Purpose: Survival outcomes in patients presenting with well-differentiated thyroid cancer with pulmonary
metastasis are variable. The aim of this study was to evaluate prognostic factors for outcome in this patient population. Methods: A prospective registry database was searched to identify patients presenting
with pulmonary metastasis from well-differentiated thyroid cancer. All patients underwent total thyroidectomy and postoperative I-131 therapy. Cox proportional hazards modeling was performed to evaluate prognostic factors for survival outcomes. Results: Forty (40) patients were identified with well-differentiated thyroid cancer involving the thyroid and metastatic to cervical lymph nodes and lung at initial
diagnosis. The median follow-up was 9.7 years for those alive at last follow-up. Cox proportional hazards modeling evaluated age at diagnosis, gender, primary tumor size, and vascular invasion on causespecific and progression-free survivals. Age at diagnosis was the only significant independent prognostic factor (p  0.0035). The 10-year cause-specific survivals were 100% in patient’s 40 years, compared
to 36% for those 40 years (p  0.0001). The corresponding 10-year progression-free survivals were
69% and 12% (p  0.0003). Conclusions: Patients 40 years of age presenting with pulmonary metastasis from well-differentiated thyroid cancer had an excellent prognosis. Older patients have a poor survival outcome. Postoperative I-131 therapy is recommended in all patients.
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INTRODUCTION
Well-differentiated thyroid carcinoma affects
both children and adults and is accompanied by
distant metastasis at the time of diagnosis in a minority of cases.1–10 Pulmonary metastases is the
most common at diagnosis and is detected in
3%–20% of patients.11–15 Pulmonary metastasis
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is more common in children and young adults9
and is associated with excellent survival after initial treatment or recurrence.16–18 Poor long-term
survival has been reported for older patients
with metastatic well-differentiated thyroid cancer,8,10,14,15,19,20 but age has not been shown to
be an independent predictor of survival in other
reports.1,6 This analysis was performed to study
the impact of prognostic factors at diagnosis on
progression-free and cause-specific survivals in
patients presenting with well-differentiated thyroid cancer and pulmonary metastasis.
MATERIALS AND METHODS
A prospective registry of patients with thyroid
cancer referred to the Mallinckrodt Institute of
Radiology (MIR; Washington University School
of Medicine, St. Louis, MO) from 1970 to 2006
was searched to identify patients with pulmonary
metastasis at time of diagnosis. Approval from
the Institutional Review Board (Washington University Human Research Protection Office) was
obtained for this study. The registry included
1333 patients with newly diagnosed, well-differentiated papillary thyroid carcinoma. None of the
patients had follicular carcinoma. Of these, 40 patients (3%) were identified with pulmonary metastasis detected on 131I scintigraphy at the time
of the initial thyroid cancer diagnosis and treatment. The size of the pulmonary metastases could
not be determined, since the information was not
recorded in the clinical records for all patients.
None of these patients were known to have a history of prior radiation exposure.
All patients underwent a total thyroidectomy and
received postoperative 131I therapy, according to
standard institutional practice. For adults, the general guideline was to administer 150–250 mCi of
131I (5.55–967.25 GBq), and children usually received the corresponding dosage adjusted for body
weight (3.57 mCi/kg, 0.13GBq/kg)). Whole-body
131I scintigraphy was performed 2–5 days after
treatment. Repeat 131I administration was performed for residual or recurrent disease. Patients received a mean 131I-administered activity of 448 mCi
(16.6 GBq) (maximum, 1400 mCi, 51.8 GBq). The
presence of pulmonary metastasis and response to
treatment were detected by whole-body scintigraphy with 131I. Persistent and recurrence disease sites
were detected by clinical examination, thyroglobulin assay, or I-131 scintigraphy. Follow-up I-131
scintigraphy was performed with 5 mCi I-131.
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Cause-specific survival is defined as death resulting from thyroid cancer. Progression-free survival is defined as the development of recurrent
thyroid cancer. Cause-specific survival and progression-free survival were estimated by using
the Kaplan-Meier method.21 The equivalence of
the survival estimates was evaluated by using the
Mantel-Cox statistic.22 Multivariate analysis was
performed by using the Cox proportional hazards
regression model.23
RESULTS
Patient Characteristics
The patient population consisted of 24 males and
16 females. Their median age was 38 years (range,
4–83). The tumor histologic type was well-differentiated thyroid cancer in all patients. None of
the patients had poorly differentiated or anaplastic carcinoma. The mean and median follow-up
times for all patients alive at the time of last follow-up were 12.3 and 9.7 years (range, 2–37).
Prognostic Factors
All patients in this study were known to have metastasis to cervical lymph nodes and lung at the
time of diagnosis. Other established prognostic
factors were evaluated by Cox multivariate proportional hazards modeling. These factors included age at diagnosis, gender, primary tumor
size, local soft-tissue invasion, and vascular invasion. Patient age was the only significant independent predictor of progression-free survival
(p  0.0061) and of cause-specific survival (p 

Figure 1.
nosis.

Cause-specific survival by age at time of diag-

0.0035). Neither gender (p  0.12), primary tumor size (p  0.15), local soft tissue invasion
(p  0.19), nor vascular invasion by tumor (p 
0.26) were independent predictors of cause-specific survival in this model.
Because age at diagnosis was the only independent prognostic factor, its effect was further
evaluated. The log-rank (Mantel-Cox) statistic
was used to determine the cut-off age value that
was strongly predictive of prognosis. It was found
that patients 40 years had a significantly better
outcome than those 40 years (Figs. 1 and 2).
The 10-year cause-specific survivals were 100%
in patients 40 years, compared to 36% for those
40 years (p  0.0001). The corresponding 10year progression-free survivals were 69% and
12%, respectively (p  0.0003).
Recurrence
Nineteen (19) of 40 patients had persistent lung
metastasis or developed new sites of recurrence
after 131I therapy. Recurrence sites are shown in
Table 1. Persistent metastatic disease in the lung
was the most common site of disease (13/19).
Twenty-one (21) patients became disease free.
DISCUSSION
The prognosis of patients presenting with pulmonary metastasis from well-differentiated thyroid cancer is variable after standard therapy. In
the current study, cause-specific survivals were
100% for patients 40 years of age and younger
and 36% in patients older than 40 years. Young

Figure 2.
agnosis.

Progression-free survival by age at time of di-

Table 1.

Recurrence Sites

Recurrence site
Cervical LN
Lung
Cervical LN  lung
Cervical LN  lung  thyroid bed
Bone
Total

Number of patients
3
6
4
3
3
19 (53%)

LN, lymph node.

age has been reported to be a positive predictor
of prolonged survival.2,8,10,14,15,19,20,24 On the
other hand, some recent reports have not found
age to be a significant independent factor.1,6 Most
investigators report young age as a predictor of
survival but fail to address the issue of what is
the cut-off age for a poor prognosis. Our data
demonstrate no cancer-related deaths for patients
less than 40 years, whereas most patients older
than 40 years will die from metastatic thyroid
cancer.
Thyroid cancer has a favorable overall prognosis in children and young adults, despite a pattern of disseminated disease and frequent recurrence.16–18,25 Cervical lymphadenopathy and
distant metastasis are more common in children
and adolescents than in adults. The inconsistency
between extensive disease at presentation and
positive outcome after therapy is characteristic of
childhood well-differentiated thyroid cancer, but
the reason for this apparently discordant behavior has not been described.25
Excellent outcome after aggressive treatment
with thyroidectomy and 131I administration for
young patients with metastatic well-differentiated thyroid cancer supports the use of 131I therapy in these patients. The positive survival results in younger patients may be explained by
less aggressive tumor biology, but 131I therapy
is recommended, based upon excellent survival
rates achieved in patients with metastasis.25,26
For older patients with pulmonary metastasis
from well-differentiated thyroid cancer, survival
may be improved through a similar approach,
using 131I administration until complete remission of disease, with multiple treatments to high
cumulative activities.19,27 A treatment protocol
that includes total thyroidectomy and postoperative 131I therapy reduces the rate of recurrence
and allows for the early detection of pulmonary
metastasis.28,29
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Uptake of 131I by pulmonary metastases from
well-differentiated thyroid cancer has been shown
to be an important factor associated with prolonged survival time.19,26 This observation underscores the important role of 131I therapy in the
successful treatment of disseminated well-differentiated thyroid cancer. 131I therapy decreases the
tumor burden in patients with pulmonary metastasis from well-differentiated thyroid cancer30 and
should be administered to patients whose tumors
concentrate 131I. Three-dimensional lung and
bone marrow dosimetry may be performed for patients with 131I-avid pulmonary metastases from
well-differentiated thyroid cancer.31,32 Use of
large cumulative activities has been reported with
minimal clinical toxicity.29,33 For older patients
with metastatic well-differentiated thyroid cancer,
the incorporation of systemic agents into therapeutic regimens may be a promising avenue for
future research, given the availability of molecularly targeted drugs27 and because of the suboptimal outcomes after standard treatment. Definitive
proof of benefit of I-131 therapy for I-131-avid
lung metastases is lacking because there is no
group of “control” or untreated patients.
CONCLUSIONS
In the current study of patients presenting with
pulmonary metastasis from well-differentiated
thyroid cancer, no deaths were observed in patients
40 years of age or younger, whereas pulmonary
metastasis was associated with a poor prognosis in
older patients. Total thyroidectomy and aggressive
postoperative 131I therapy are recommended for all
patients with pulmonary metastasis from well-differentiated thyroid cancer, and this treatment regimen provides optimal long-term survival for patients aged 40 years or younger.
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